Parkinson’s Disease Therapeutics Market To Report Impressive Growth, Revenue To Touch US$4.31 Billion By 2023

11-May-2018 | Zion Market Research

With the presence of a large pool of participants, the Global Parkinson’s disease therapeutics market is displaying a highly competitive business landscape, finds a new research report by Zion Market Research (ZMR). Novartis AG, F. Hoffmann-La Roche AG, AbbVie Inc, Teva Pharmaceutical Industries Ltd, and GlaxoSmithKline plc are some of the key vendors of Parkinson’s disease therapeutics across the world. These players across Parkinson’s disease therapeutics market are focusing aggressively on innovation, as well as on including advanced technologies in their existing products. Over the coming years, they are also expected to take up partnerships and mergers and acquisitions as their key strategy for business development, states the Parkinson’s disease therapeutics market study.

Citing an instance, on September 6, 2018, Yumanity Therapeutics, a firm focusing on discovering transformative methods to treat neurodegenerative disorders, declared that its leading drug YTX-7739 will be introduced in IND-supporting research for treating Parkinson’s ailment & associated disorders.  Reportedly, the clinical candidate is a new therapeutic that is predicted to play a vital role in treatment of Parkinson disease. Sources cite that the drug is likely to enter initial in-human studies by the end of 2019.

Request Sample Request Customization Buy Now

Browse the full "Parkinson’s Disease Therapeutics Market by Drug Class (Levodopa Combination, Dopamine Agonists, Monoamine Oxidase B (MAO-B) Inhibitors, Anticholinergic Drugs, Catechol-O-Methyltransferase (COMT) Inhibitors and Others), by Route of Administration (Oral, Transdermal, Subcutaneous, and Intestinal Infusion) and by Distribution Channel for Hospital Pharmacy, Retail Pharmacy and Online Sales: Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2023" report at

As estimated in this report, the global Parkinson’s disease therapeutics market stood at US$ 2.36 billion in 2017. Witnessing a tremendous rise during the period from 2017 to 2023, the revenue in this Parkinson’s disease therapeutics market is expected to reach US$ 4.31 billion by the end of the forecast period. The main drug types available in this Parkinson’s disease therapeutics market are Levodopa Combination, Dopamine Agonists, Monoamine Oxidase B (MAO-B) Inhibitors, Anticholinergic Drugs, and Catechol-O-Methyltransferase (COMT) Inhibitors. Among them, the demand for Levodopa combination drug is relatively higher and the trend is anticipated to remain so over the next few years, notes the research report.

Global Parkinson’s Disease Therapeutics Market

Rising Incidences Of Parkinson In Developed Countries To Impel Growth

“Mounting cases of Parkinson disease witnessed in developed economies is anticipated to drive the growth of Parkinson’s disease therapeutics market in the years ahead,” says the author of this Parkinson’s disease therapeutics study. Apart from this, growing awareness about the disease along with large allocation of government budget for R&D activities is projected to accelerate Parkinson’s disease therapeutics market trends in the near future.

Patent expiration of branded drugs along with side-effects related to therapeutic medicines, however, is projected to hinder the expansion of Parkinson’s disease therapeutics market over the forecast timeframe.

Humungous Demand For Clinical Pipeline Drugs to Support Europe’s Dominance

Regionally, Europe has been leading the worldwide Parkinson’s disease therapeutics market and is anticipated to continue on the dominant position in the years to come, states the Parkinson’s disease therapeutics market study. Elevated awareness levels, favorable medical insurance & reimbursement policies, and demand for clinical pipeline drugs are the key factors behind the dominance of the Europe Parkinson’s disease therapeutics market. Massive funding of R&D projects by non-profit organization & government along with rapid expansion of geriatric population prone to the disease is another significant factor that is supporting the growth of this regional Parkinson’s disease therapeutics market.

The global Parkinson’s disease therapeutics market is segmented as follows:

By Drug Class

  • Levodopa Combination
  • Dopamine Agonists
  • Monoamine Oxidase B (Mao-B) Inhibitors
  • Anticholinergic Drugs
  • Catechol-O-Methyltransferase (Comt) Inhibitors
  • Others

By Route of Administration 

  • Oral
  • Transdermal
  • Subcutaneous
  • Intestinal Infusion

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales

By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651

Download Brochure
Latest Published Reports

View All Published Reports